A specialty pharmacy carries a different audit exposure than a retail pharmacy filling maintenance medications. A single flagged claim on a high-cost biologic can represent more dollars than an entire month of ordinary retail claims, so a narrow error rate on a PBM audit of specialty dispensing can still produce a six-figure recoupment demand. Specialty-focused audit programs also test more than individual claims. They test whether the pharmacy still holds the limited-distribution drug (LDD) network agreements and the URAC or ACHC accreditation that got it into the network in the first place.
Why High-Dollar Claims Draw Heavier Scrutiny
Specialty drugs used to treat rare, chronic, or complex conditions routinely carry per-claim costs many times higher than a standard maintenance prescription. That dollar concentration changes the math on both sides of an audit. A PBM's recovery per finding is larger, which raises the incentive to flag specialty claims for review, and the same finding rate that a retail pharmacy could absorb becomes a substantial exposure once it is applied across a specialty book of business. Auditors frequently examine inventory reconciliation on these high-cost drugs alongside claims data, a pattern our companion piece on inventory shortage findings in PBM audits addresses in more detail.
Limited-Distribution Drug Network Conditions
A limited-distribution drug is one a manufacturer chooses to dispense through a small, contracted set of specialty pharmacies rather than through the open market. The manufacturer selects pharmacies based on their ability to provide clinical support, adverse-event and outcomes reporting, and patient monitoring for the specific therapy. Access to that network is governed by the manufacturer agreement, not by the pharmacy's state license alone, and PBMs commonly treat continued LDD network status as a condition of specialty formulary participation. A pharmacy that loses its place in a manufacturer's limited-distribution network can lose the ability to bill for that drug entirely, independent of how any single claim performed on audit.
Accreditation as a Condition of Network Access
PBMs and manufacturers commonly condition specialty network participation on third-party accreditation. URAC's Specialty Pharmacy Accreditation is a three-year credential evaluated across operational areas that include patient management, medication distribution, cold-chain integrity, clinical safety, and quality reporting. ACHC's Specialty Pharmacy Accreditation evaluates the same core areas of quality and safety, with added distinctions available for oncology and rare disease and orphan drug dispensing. Both organizations use scheduled and, at times, unscheduled reviews to confirm a pharmacy still meets the standard it was accredited against. A gap between what a pharmacy represented at accreditation and what its operations actually show is a finding a PBM specialty audit will look for on its own.
A specialty pharmacy can pass every individual claim in an audit and still lose network access if its accreditation standing or its limited-distribution agreements lapse.
Documentation That Survives a Specialty Audit
Specialty audits scrutinize the full prior authorization chain behind each dispensed claim, not just the authorization number on file, and they check patient assistance program records for consistency with the manufacturer's own eligibility terms. Where the drug carries a Risk Evaluation and Mitigation Strategy (REMS), the FDA requires the dispensing pharmacy to complete certification for that REMS program and, for many products, to document the specific safe-use condition, such as a lab result or prescriber attestation, before the drug goes out the door. A pharmacy that cannot produce that certification and safe-use documentation on request is exposed on the claim even when the clinical care behind it was sound. A specialty audit that surfaces this kind of documentation gap across a pattern of claims can escalate toward an audit appeal or, in the more serious cases, toward network termination.
Why Early Legal Counsel Is Critical
It is critical that specialty pharmacies retain experienced healthcare defense counsel promptly upon receiving a specialty-focused audit notice, an accreditation deficiency letter, or a manufacturer inquiry into limited-distribution network status. Early legal intervention can protect the pharmacy's rights, ensure the audit response is built on documentation the PBM or manufacturer will credit, avoid inadvertent admissions in written correspondence, and preserve the pharmacy's position if a finding threatens accreditation or network status rather than a single claim. Delaying counsel until after a response deadline has passed can foreclose defenses that were available at the outset.
How Health Law Alliance Can Help
Health Law Alliance defends specialty pharmacies nationwide against PBM audit findings tied to high-dollar claims, limited-distribution network disputes, and accreditation-related deficiencies. Our bench includes a former federal prosecutor and a former senior pharmacy benefit manager executive, background that shapes how we evaluate which specialty findings hold up and which do not. If your pharmacy has received a specialty audit notice or a network status inquiry, contact us for a free, confidential consultation.
